– · Messe Düsseldorf
MEDICA 2026
Meet the AiMediq team at our booth. Book a meeting for a clinic conversation, a scientific discussion or a partnership.
Hall 11 · Stand H66
by AiMediq
The AiMediq team
Two medical inventions
created a new medical method.
Each patient’s response guides the dose.
The AiMediq team invented medical intermittent hypoxic–hyperoxic treatment (IHHT®) and a system for individual physiological dosing.
The ReOxy® medical device implements both inventions. SRT® adapts oxygen exposure and recovery to the patient’s measured physiological response.
Intended use: improvement of physical exercise capacity in adult and senior patients with coronary artery disease (CAD).
For use in a clinical environment under professional supervision and according to a doctor's prescription.
Oxygen exposure
SpO₂ response
Start with your role
Find the device information, research or practical next step relevant to you.
- 01 For clinics The device, clinical evidence and practical questions for introducing ReOxy® into your clinic. Open
- 02 For healthcare professionals Request the Instructions for Use, technical information and ReOxy publications from our medical team. Request information
- 03 For researchers Research collaboration, the scientific programme and how to request publications. Open
- 04 For patients and families What happens in a session, questions to ask your doctor and how to find a clinic. Open
- 05 For distribution partners Explore distribution, discuss your market and preview the partner workspace. Open
Assess · Guide · Document
ReOxy doses hypoxia by physiology.
In IHHT®, phases of reduced oxygen (hypoxic phase) alternate with phases of increased oxygen (hyperoxic recovery phase).
Response dynamics during IHHT® cycles
Illustrative reconstruction — not patient data- Oxygen exposure (FiO₂)
- Measured response (SpO₂)
- Baseline SpO₂
- Hypoxic phase
- Hyperoxic recovery phase
-
01 · ASSESS
Hypoxic Test
The Hypoxic Test characterises the individual oxygen-saturation and pulse response before treatment. The supervising physician confirms the treatment parameters.
-
02 · GUIDE
SRT® Technology
SRT® Technology uses the measured physiological response to guide hypoxic exposure and hyperoxic recovery throughout the treatment.
-
03 · DOCUMENT
Reports and records
Automatic test and treatment reports and session traceability for clinical workflows; storage for up to 1,000 patients and 100,000 reports.
Continuous measurement
ReOxy continuously measures SpO₂ and pulse rate using Masimo SET® pulse oximetry and displays perfusion index. The supplied-gas flow trace represents breathing pattern.
ReOxy® implements ICU/CCU-grade SpO₂ monitoring integrated into the measurement and control architecture.
Gold standard Masimo SET® pulse oximetry
- SpO₂
- Pulse rate
- Perfusion index
- Breathing pattern
Layered safety
Layered safety concept: treatment requires valid signal readings; defined response boundaries trigger protective action; continuous system supervision provides clear status messages and prioritised alerts.
For use in a clinical environment under professional supervision and according to a doctor's prescription.
See the Instructions for Use for contraindications, warnings and precautions.
Purpose-designed for ReOxy®
Three processors.
Hardware-separated functions.
Three-level, three-processor architecture with redundant hardware-separated measurement, multi-valve-dosing (instant-mixing technology) and safety control.
More than 90% of components have been specifically designed for the ReOxy® medical device.
Explore the engineeringQuality and manufacturing
Engineering, manufacturing and quality
-
01
Medical-device engineering
AiMediq's dosing principle became ReOxy® through medical-device engineering with Bitmos — respiratory technology, patient monitoring and medical software. Gas-system performance and quality are checked in a dedicated test facility, separate from assembly.
-
02
Manufacturing and quality system
Manufactured in Germany: ReOxy® is serially manufactured by Bitmos GmbH, Düsseldorf. Bitmos' quality management system is certified to EN ISO 13485:2016 by TÜV Rheinland (SX 1010072-1).
About AiMediq
The idea, the inventors and the medical device
AiMediq developed medical IHHT® and made it individually doseable.
The AiMediq team began developing medical IHHT® at VNIIMI before Ai Mediq S.A. was incorporated in Luxembourg in 2010. The documented sequence includes the 2005 method application, the 2008 response-guided control applications and the later European patent EP 3 452 154 B1.
- Milestones: 2005 IHHT® method
- 2008 response-guided control
- 2011 ReOxy prototype with Bitmos
- 2014 Signed Class IIb declaration under Directive 93/42/EEC
- 2018–2019 two European Commission Seals of Excellence for ReOxy grant proposals (Horizon 2020).
The Seals recognise the quality of the ReOxy grant proposals. They are separate from the ReOxy4Heart proposal and do not certify clinical efficacy or indicate awarded funding. Explore the history and sources.
Our story · Alexey Platonenko, Managing Director
The dose had to follow the patient
A clinical question brought our team together: how could a hypoxic stimulus be individually dosed for medical treatment? Alexey Platonenko traces the work from clinical experience and individual dosing to the ReOxy medical device and the research that continues today.
Read our storyScientific programme
Research collaboration
AiMediq continues an established ReOxy-specific clinical research programme on individually dosed IHHT®.
Collaborate on the next research questions, protocols and outcome measures.
We welcome research partners.
Published studies with ReOxy® are available to healthcare professionals and researchers on request from our medical team.
Events
Meet us
-
-
2027 · Online
Scientific webinars
Webinars and scientific meetings for healthcare professionals. Dates to be announced.
-
2027 · Europe
Cardiology and rehabilitation congresses
Where to find us in 2027. Dates and locations to be announced.